All In MedTech

Device Trial Radar · NCT03556696

Automatic Remifentanil Administration Guided by ANI During Propofol Anesthesia

Automatic Remifentanil Administration Guided by the Analgesia Nociception Index During Propofol Anesthesia

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jun 27, 2018

Primary completion

Jun 14, 2022

Study completion Nov 22, 2022

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 14, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective Randomized Monocentric Clinical Trial during propofol anesthesia. The aim of the study is to test whether the use of a medical device designed to automatically administer remifentanil during surgery based on expert rules and continuous reading of heart rate, blood pressure and the Analgesia Nociception Index results in lower overall remifentanil administration versus standard practice.

Conditions

  • Nociceptive Pain
  • Surgical Procedure, Unspecified

Interventions

  • ANI-REMI-loopDevice

    experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration

  • remifentanil pK/pD target administration deviceDevice

    standard practice, remifentanil administration using Minto's pK/pD model

  • RemifentanilDrug

    Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.

  • PropofolDrug

    propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range

  • ANI monitorDevice

    ANI (Analgesia Nociception Index) value is used in the "std\_practice" arm for guidance of the remifentanil Ce target

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. normalized remifentanil administrationTime frame: During the surgery, an average Three hours and a half

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Roger Salengro, CHU

    Lille, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.